



UK Health
Security
Agency

National Influenza and COVID-19 surveillance report

Week 27 report (up to week 26 data)

6 July 2023

Contents

Executive summary	4
Laboratory surveillance	6
Confirmed COVID-19 cases (England).....	6
Respiratory DataMart system (England).....	8
Community surveillance	10
Acute respiratory infection incidents	10
Syndromic surveillance.....	12
Primary care surveillance	13
RCGP Clinical Indicators (England).....	13
RCGP sentinel swabbing scheme in England	14
Secondary care surveillance	18
Hospitalisations, SARI Watch	18
ICU or HDU admissions, SARI Watch	20
ECMO, SARI Watch	23
RSV admissions, SARI Watch.....	24
Mortality surveillance	25
COVID-19 deaths	25
Daily excess all-cause mortality (England)	25
Microbiological surveillance	26
SARS-CoV-2 variants.....	26
COVID-19 vaccination.....	28
COVID-19 vaccine uptake in England	28
International update	30
Global COVID-19 update.....	30
Global influenza update.....	30
Other respiratory viruses	33
Related links	35
About the UK Health Security Agency	36

National Influenza and COVID-19 Report: week 27 report (up to week 26 data)

For additional information including regional data on COVID-19 and other respiratory viruses, COVID-19 in educational settings, co- and secondary infections with COVID-19 and other data supplementary to this report, please refer to the [accompanying graph pack](#).

For additional information regarding data source please refer to [Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#)

Executive summary

This report summarises the information from the surveillance systems which are used to monitor coronavirus (COVID-19), influenza, and other seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 26 (between 26 June and 2 July 2023) and for some indicators daily data up to 4 July 2023.

Overall

In week 26, from most indicators, influenza activity remained stable and COVID-19 activity decreased.

COVID-19

COVID-19 case rates through Pillar 1 decreased in all ethnic groups and most age groups in week 26.

Through Respiratory Datamart, SARS-CoV-2 positivity increased slightly to 3.6% compared to the previous week.

The overall number of reported SARS-CoV-2 confirmed outbreaks decreased compared to the previous week. Two SARS-CoV-2 confirmed outbreaks were reported in week 26 in England.

Overall, COVID-19 hospitalisations and ICU admissions decreased in week 26 compared to the previous week. Hospitalisations were highest in the 85 years and over age group. Through syndromic surveillance indicators, emergency department attendances for covid-like illness remained stable nationally.

Influenza

In week 24, influenza remained low and stable at 0.4% compared to the previous week, with highest positivity seen in the 15 to 44 years old age group at 1.1%.

Through primary care surveillance, the influenza-like-illness consultations indicator remained stable in week 26 compared to the previous week and was within the baseline activity level range.

No influenza confirmed outbreaks were reported in week 26 in England.

Influenza ICU admissions remained low and stable in week 26 and remained within the baseline range of activity.

Emergency department attendances for influenza-like illness remained stable nationally.

RSV

The overall positivity for RSV remained low at 0.2%, with the highest positivity in those aged under 5 years old at 1.2%. Emergency department attendances for acute bronchiolitis remained stable nationally.

Other viruses


Adenovirus positivity remained low at 2.4%, with the highest positivity in the 5 to 14 year olds age group at 7.8%. Human metapneumovirus (hMPV) positivity remained low at 0.3%, with the highest positivity in the 5 to 14 year olds age group at 1.2%. Parainfluenza positivity decreased slightly to 3.0%, with the highest positivity in the 5 to 14 year olds age group at 5.0%. Rhinovirus positivity decreased slightly to 9.7% overall, with the highest positivity in those aged under 5 years old at 18.4%.

Laboratory surveillance

Confirmed COVID-19 cases (England)


As of 9am on 2 July 2023, a total of 2,104,146 episodes have been confirmed for COVID-19 in England under Pillar 1, and 18,744,451 episodes under Pillar 2, since the beginning of the pandemic. COVID-19 case rates through Pillar 1 decreased in all ethnic groups and most regions in week 26.

Figure 1: Confirmed COVID-19 episodes tested under Pillar 1, based on sample day with overall seven-day rolling average PCR positivity for Pillar 1 (%)




Age

Figure 2: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by age group



Geography

Figure 3: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by UKHSA centres



Respiratory DataMart system (England)

In week 26, data is based on reporting from 12 out of the 16 sentinel laboratories.

In week 26, 4,535 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. 165 samples were positive for SARS-CoV-2 with an overall positivity of 3.6%, which increased slightly compared to the previous week. The highest positivity was seen in the 65 years old and over at 4.9%.

In week 26, 2,534 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. Nine samples tested positive for influenza; five influenza A(not subtyped), two influenza A(H3N2) and two influenza B (Figure 4). Overall, influenza positivity remained low at 0.4% in week 26 compared to the previous week, with the highest positivity seen in the 15 to 44 year olds age group at 1.1%.

Adenovirus positivity remained low at 2.4%, with the highest positivity in the 5 to 14 year olds age group at 7.8%.

Human metapneumovirus (hMPV) positivity remained low at 0.3%, with the highest positivity in the 5 to 14 year olds age group at 1.2%.

Parainfluenza positivity decreased slightly to 3.0%, with the highest positivity in the 5 to 14 year olds age group at 5.0%.

Rhinovirus positivity decreased slightly to 9.7% overall, with the highest positivity in those aged under 5 years old at 18.4%.

The overall positivity for RSV remained low at 0.2%, with the highest positivity in those aged under 5 years old at 1.2%.

Figure 4: Respiratory DataMart samples positive for influenza and weekly positivity (%) for influenza, England





Figure 5: Respiratory DataMart weekly positivity (%) for other viruses, England



Community surveillance

Acute respiratory infection incidents

Here we present data on acute respiratory infection (ARI) incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs).

17 new ARI incidents have been reported in week 26 in the UK:

- Eight incidents were from care homes, where six had at least one linked case that tested positive for SARS-CoV-2 and one for rhinovirus
- Eight incidents were from hospitals, where seven had at least one linked case that tested positive for SARS-CoV-2
- One incident was from other settings, with no test result available

Figure 6: Number of acute respiratory infection (ARI) incidents by setting, England





Figure 7: Number of acute respiratory infection (ARI) incidents in all settings by virus type, England



Syndromic surveillance

During week 26, NHS 111 calls for cold or flu and cough decreased and were below baseline levels. GP in hours consultation rates for influenza-like illness were stable and similar to baseline levels. Emergency department attendances (ED) for influenza-like illness remained stable nationally and similar to baseline levels. ED for acute respiratory infection decreased nationally and were similar to baseline levels. ED for acute bronchiolitis remained stable nationally and below baseline levels. ED for covid-19-like illness remained stable nationally.



For further information on syndromic surveillance please see the [Syndromic Surveillance: weekly summaries](#).

Primary care surveillance

RCGP Clinical Indicators (England)

The weekly ILI consultation rate through the RCGP surveillance remained stable at 0.9 per 100,000 registered population in participating GP practices in week 26 and was within baseline activity levels (less than 11.47 per 100,000) (Figure 8).

Figure 8: RCGP influenza-like illness (ILI) consultation rates, all ages, England




RCGP sentinel swabbing scheme in England

Based on the date samples were received in the reference laboratory, in week 26 2023 (week commencing 26 June 2023) 108 samples were tested through the GP sentinel swabbing scheme in England, of which 20 samples tested positive (Figure 9). Among all positive samples, 60.0% were for rhinovirus, 30.0% for adenovirus and 10.0% for SARS-CoV-2 (Figure 10).

Based on the date samples were taken, influenza positivity decreased, SARS-CoV-2 positivity increased slightly and RSV positivity remained stable in week 26 compared to the previous week (Figure 11). Data for the most recent week will be updated retrospectively. Positivity (%) is not calculated when the total number tested based on sample date is less than 20 (Figure 11).


Figure 9: Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing



Unknown category corresponds to samples with no result yet.


Source: RCGP Research and Surveillance Centre sentinel primary care practices ([RCGP Virology Dashboard](#))

Figure 10: Proportion of detections of SARS-CoV-2, influenza, and other respiratory viral strains amongst virologically positive respiratory surveillance samples in England by week, GP sentinel swabbing scheme



Source: RCGP Research and Surveillance Centre sentinel primary care practices ([RCGP Virology Dashboard](#))

Figure 11: Weekly positivity (%) for COVID-19, Influenza and RSV in England by week, GP sentinel swabbing




Secondary care surveillance

Hospitalisations, SARI Watch

In week 26 (ending 2 July 2023), the overall weekly hospital admission rate for COVID-19 decreased to 0.89 per 100,000 compared to 1.29 per 100,000 in the previous week, the lowest rate in 2023. The last time the rate was similarly low was in week 21 2021 (late May 2021).

By UKHSA centre, the highest hospital admission rate for COVID-19 was observed in London. By age group, the highest hospital admission rate for confirmed COVID-19 continues to be in those aged 85 years old and over.


Figure 12: Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, SARI Watch, England



* COVID-19 hospital admission rate based on 83 NHS trusts for week 26

* SARI Watch data is provisional and subject to retrospective updates

Figure 13: Weekly hospital admission rate by age group for new COVID-19 positive cases




ICU or HDU admissions, SARI Watch

In week 26 (ending 2 July 2023), the overall weekly ICU or HDU admission rate for COVID-19 remained very low, decreasing slightly to 0.04 per 100,000, compared to 0.06 per 100,000 in the previous week. The last time the rate was similarly low was in week 33 2020. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward.

In week 26, the overall ICU or HDU rate for influenza remained stable at 0.00 per 100,000 compared to 0.00 per 100,000 in the previous week. The rate in the latest week remained at baseline activity levels. There were no new case reports of an ICU or HDU admission for influenza in week 26.

Figure 14: Weekly overall COVID-19 ICU or HDU admission rates per 100,000 trust catchment population, SARI Watch, England



* COVID-19 ICU or HDU admission rate based on 73 NHS trusts for week 26

* SARI Watch data is provisional and subject to retrospective updates

Figure 15: Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, SARI Watch, England





Figure 16: Weekly influenza ICU or HDU admissions by influenza type, SARI Watch, England




ECMO, SARI Watch

There was one new ECMO admission reported in week 26 from the 7 Severe Respiratory Failure (SRF) centres in the UK. The admission was not due to an acute respiratory infection.

RSV admissions, SARI Watch

Data on hospitalisations, including ICU or HDU admissions, with respiratory syncytial virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel.

Figure 17: Weekly hospitalisation (including ICU or HDU) admission rates by age group for new RSV cases reported through SARI Watch, England



* SARI Watch data is provisional

* Please note that rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000

Mortality surveillance

COVID-19 deaths

For further information on COVID-19 related deaths in England please see the [COVID-19 dashboard for death](#).

Daily excess all-cause mortality (England)

For further information on excess all-cause mortality in England please see the [Fingertips excess mortality in England report](#), which uses ONS death registration data and the [all-cause mortality surveillance report](#), which uses the EuroMOMO model to measure excess deaths.

Microbiological surveillance

SARS-CoV-2 variants

UKHSA conducts genomic surveillance of SARS-CoV-2 variants.

This section provides an overview of new and current circulating variants in England.

Detailed surveillance of particular variants of concerns can be found in recent [technical briefings](#).


Information on whole genome sequencing coverage can be found in the accompanying slide set.

The prevalence of different UKHSA-designated variants amongst sequenced episodes is presented in Figure 18.

Variants may include many sub-lineages that have not been individually designated e.g. XBB.1.9.2 within XBB (V-22OCT-02). As a result, prevalence of that variant appears to be increasing as a whole, masking the effect of one or more growing sublineages. Once a sublineage meets required thresholds to be declared a variant, it will be designated as a variant and prevalence of this sublineage in positive cases will then be identifiable in the data.

To account for sequencing delays, we report the proportion of variants from sequenced episodes between 12 June 2023 and 18 June 2023. Of those sequenced in this period, 25.8% were classified as XBB.1.16 (V-23APR-01), 14.0% as XBB.1.5 (V-23JAN-01), 57.5% as XBB (V-22OCT-02), 1.6% as CH.1.1 (V-22DEC-01), 0.5% as BQ.1 (V-22OCT-01), and 0.5% as BA.5 (V-22APR-04).

Figure 18: Prevalence of SARS-CoV-2 variants amongst available sequences episodes for England from 10 July 2022 up to 25 June 2023



The grey line indicates proportion of cases sequenced.

The vertical dashed lines (red) denote changes in policies:

- Line 1: End of August 2022 denotes the change in asymptomatic testing
- Line 2: April 2023 denotes changes in PCR testing in social care and hospital settings

Note: Recombinants such as XD, are not specified but are largely within the 'Other' group currently as numbers are too small.


COVID-19 vaccination

COVID-19 vaccine uptake in England

By the end of week 26 2023 (week ending 2 July 2023), 71.1% (3,856,204 out of 5,423,074) of all people aged over 75 years old who are living and resident in England had been vaccinated with a Spring 2023 booster dose since 3 April 2023 (Figure 19).

By the end of week 26 2023 (week ending 2 July 2023), 41.2% (915,421 out of 2,223,120) of all people aged 5 years and over who are immunosuppressed and living and resident in England had been vaccinated with a Spring 2023 booster dose since 3 April 2023 (Figure 19).

Figure 19: Cumulative weekly COVID-19 vaccine uptake in those who are living and resident in England vaccinated with a Spring 2023 booster since 3 April 2023*



*Please note that this graph shows data for the Spring 2022 campaign and does not correspond to the date axis but is aligned to the current Spring 2023 campaign to allow comparison of both.

International update

Global COVID-19 update

For further information on the global COVID-19 situation please see the [World Health Organization \(WHO\) COVID-19 situation reports](#).

Global influenza update

Updated 26 June 2023 (based on data up to 11 June 2023) ([WHO website](#)).

Globally, influenza detections remained low, but in the southern hemisphere, some countries reported variable changes in influenza detections in recent weeks while detections in other countries seemed to have peaked.

In Oceania, influenza activity continued to increase with influenza A viruses predominant.

In South Africa, influenza activity decreased but remained at a moderate level in pneumonia and decreased to a low level in influenza-like illness (ILI) surveillance with influenza A viruses predominately detected.

In temperate South America, influenza activity appeared to decrease with A(H1N1)pdm09 viruses most frequently detected followed by B viruses, mainly reflecting an apparent decrease in Chile. Variable activity was reported in other countries.

In the Caribbean countries, influenza activity remained low overall. In the Central American countries, increased influenza activity was reported in a few countries with A(H1N1)pdm09 most frequently detected followed by B/Victoria lineage viruses.

In the tropical countries of South America, overall influenza activity decreased with detections of predominantly A(H1N1)pdm09 and B viruses.

In tropical Africa, influenza detections were low in reporting countries. Influenza A(H1N1)pdm09 viruses predominated among reported detections.

In Southern Asia, influenza activity remained low with all seasonal subtypes detected.

In South-East Asia, influenza activity remained stable in most reporting countries, with continued reporting of predominantly A(H1N1)pdm09 and A(H3N2) virus detections.

In the temperate zones of the northern hemisphere, influenza activity was reported at low levels or below seasonal threshold in most reporting countries. All seasonal influenza subtypes were detected in similar proportions overall.

The WHO GISRS laboratories tested more than 262,237 specimens during that time period. 6,709 were positive for influenza viruses, of which 4,221 (62.9%) were typed as influenza A and 2,488 (37.1%) as influenza B. Of the sub-typed influenza A viruses, 2009 (73.6%) were influenza A(H1N1)pdm09 and 719 (26.4%) were influenza A(H3N2). Of the type B viruses for which lineage was determined, all (321) belonged to the B/Victoria lineage.

Influenza in Australia

Updated 30 June 2023 (based on data up to fortnight ending 25 June 2023) ([Australian Government website](#)).

Australia monitors influenza through a number of complementary systems. The Australian government advises caution in the interpretation of data reported from various influenza surveillance systems due to the effects of COVID-19, particularly when making inter-season comparisons. Caution should also be applied in assessing the implications of influenza activity in Australia to the UK. It is not possible to reliably predict the course of the 2023 southern hemisphere influenza season or the implications for the following 2023 to 2024 northern hemisphere season, such as the timing, activity and impact of the 2023 to 2024 influenza season in the UK. Australia is one of many countries from which flu may arrive in the UK, including other countries which are more populous and or have more frequent inbound travel. Australia's influenza activity reflects its specific epidemiological circumstance and has no bearing on the local persistence of influenza in the UK in our inter-seasonal period.

Influenza-like-illness (ILI) activity in the community and hospitalisations due to influenza at sentinel hospitals stabilised this fortnight, while ILI presentations to sentinel general practitioners (GPs) decreased. In the year-to-date (1 January to 25 June 2023), there have been 116,473 notifications reported to the National Notifiable Diseases Surveillance System (NNDSS) in Australia, of which 29,315 notifications had a diagnosis date this fortnight. In the year to date, notification rates have been highest in people aged 5 to 9 years, followed by those aged 0 to 4 years, and 10 to 14 years.

There is currently not enough information to comprehensively assess the potential severity of the 2023 influenza season at this time. In the year-to-date, of the 116,473 notifications of laboratory-confirmed influenza, 107 influenza-associated deaths have been notified to the NNDSS. Since seasonal surveillance commenced in April 2023, there have been 1,236 sentinel hospital admissions with influenza, of which 80 (6.5%) were admitted directly to ICU.

In the year to date, 69% of notifications of laboratory-confirmed influenza reported to the NNDSS were influenza A, of which 95% were influenza A(untyped); 4% were influenza A(H1N1); and 1% were influenza A(H3N2). Influenza B accounted for 29% of notifications; influenza A and B accounted for 0.2% of notifications; and 2% of influenza notifications were untyped.

Of the 1,679 samples referred to the WHO Collaborating Centre for Melbourne (WHOCC) in the year-to-date, 97.4% of influenza A(H1N1) isolates, 79.1% of influenza A(H3N2) isolates, and 99.0% of influenza B/Victoria isolates characterised were antigenically similar to the corresponding vaccine components. It is too early to assess vaccine effectiveness for this season.

For further information on influenza in Australia please see the [Australian Influenza Surveillance Report and Activity Updates](#).

Other respiratory viruses

Avian influenza and other zoonotic influenza

[Latest WHO update on 31 May 2023](#)

From 25 April to 31 May 2023, one human case of infection with an influenza A(H1N2) variant virus, two human cases with positive influenza A(H5N1) detections, one human case of infections with an influenza A(H5N6) virus, and one human case of infection with an influenza A(H9N2) virus were reported officially.

The overall public health risk from currently known influenza viruses at the human-animal interface has not changed, and the likelihood of sustained human-to-human transmission of these viruses remains low. Human infections with viruses of animal origin are expected at the human-animal interface wherever these viruses circulate in animals.

UKHSA has detected influenza A(H5) virus in two poultry workers, following the introduction of an asymptomatic testing programme for people who have been in contact with infected birds. See the [UKHSA press release 16 May 2023](#) for more information.

[Latest UKHSA avian influenza technical briefing 2 June 2023](#)

See also the [WHO Disease Outbreak News Reports](#) for more information.

Middle East respiratory syndrome coronavirus (MERS-CoV)

From April 2012 to May 2023, a total of 2,604 laboratory-confirmed cases of MERS-CoV and 936 associated deaths were reported globally to [WHO](#) under the International Health Regulations (IHR 2005).

Between 29 December 2021 and 31 October 2022, four laboratory-confirmed cases of MERS-CoV were reported to WHO by the Ministry of Health of the Kingdom of Saudi Arabia. No deaths were reported ([WHO website](#)).

On 28 April 2022, the National IHR Focal point of Oman notified WHO of one case of MERS-CoV in Oman ([WHO website](#)).

Between 22 March and 3 April 2022, the National IHR Focal Point of Qatar reported 2 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection to the WHO ([WHO website](#)).

A total of 5 cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (3 imported and 2 linked cases) have been confirmed in the UK through ongoing surveillance since September 2012.

[Further information on management and guidance of possible cases](#) is available online. The latest [ECDC MERS-CoV risk assessment](#) highlights that risk of widespread transmission of MERS-CoV remains very low.

Related links

[Previous national COVID-19 reports](#)

[Previous weekly influenza reports](#)

[Annual influenza reports](#)

[COVID-19 vaccine surveillance reports](#)

[Previous COVID-19 vaccine surveillance reports](#)

[Public Health England \(PHE\) monitoring of the effectiveness of COVID-19 vaccination](#)

[Investigation of SARS-CoV-2 variants of concern: technical briefings](#)

[Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#)

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.

About the UK Health Security Agency

The [UK Health Security Agency](#) is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2023

Prepared by: Immunisation and Vaccine Preventable Diseases Division
For queries relating to this document, please contact: Enquiries@ukhsa.gov.uk

Published: 6 July 2023



You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN
Sustainable Development Goals

